**Reference list of eligible studies**

1. **Arnold2004 (HMBO)**
* Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomised double-blind placebo-controlled trial. JClin Psychiatry. 2002 Apr;63(4):308-15.z
1. **Arnold2005 (HMCA, NCT00489073)**
* Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomised, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119(1-3):5-15.
* <https://clinicaltrials.gov/ct2/show/NCT00489073>
1. **Arnold2010 (HMGB, NCT00673452)**
* Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomised, double-blind, placebo-controlled trial. The Journal of rheumatology 2010;37(12):2578-86.
* <https://clinicaltrials.gov/ct2/show/NCT00673452>
1. **Arnold2012 (HMGG, NCT00965081)**
* Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomised, double-blind, placebo-controlled study. The Clinical journal of pain 2012;28(9):775-81.
* <https://clinicaltrials.gov/ct2/show/NCT00965081>
1. **Baldwin2012 (11984A, NCT00635219)**
* Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012 Jul;22(7):482-9
* <https://clinicaltrials.gov/ct2/show/NCT00635219>
1. **Bent2008 (SBBO, NCT00190814)**
* Bent AE, Gousse AE, Hendrix SL, Klutke CG, Monga AK, Yuen CK, Muram D, Yalcin I, Bump RC. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. Neurourology and urodynamics 2008;27(3):212-21.
* <https://clinicaltrials.gov/ct2/show/NCT00190814>
1. **Boulenger2014 (13267A, NCT01140906)**
* Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomised, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138-49
* <https://clinicaltrials.gov/ct2/show/NCT01140906>
1. **Brannan2005 (HMCB, NCT00036335)**
* Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. Journal of psychiatric research 2005;39(1):43-53.
* <https://clinicaltrials.gov/ct2/show/NCT00036335>
1. **Brecht2007 (HMDH, NCT00191919)**
* Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomised controlled trial. The Journal of clinical psychiatry 2007;68(11):1707-16.
* <https://clinicaltrials.gov/ct2/show/NCT00191919>
1. **Cardozo2004 (SBAM, NCT00190619)**
* Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstetrics and gynecology 2004;104(3):511-9.
* <https://clinicaltrials.gov/ct2/show/NCT00190619>
1. **Cardozo2010 (SBCC, NCT00190996)**
* Cardozo L, Lange R, Voss S, Beardsworth A, Manning M, Viktrup L, Zhao YD. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence. Current medical research and opinion 2010;26(2):253-61.
* <https://clinicaltrials.gov/ct2/show/NCT00190996>
1. **Castro-Diaz2007 (SBBR, NCT00190827)**
* Castro-Diaz D, Palma PC, Bouchard C, Haab F, Hampel C, Carone R, Zepeda Contreras S, Rodriguez Ginorio H, Voss S, Yalcin I, Bump RC. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. International urogynecology journal and pelvic floor dysfunction 2007;18(8):919-29.
* <https://clinicaltrials.gov/ct2/show/NCT00190827>
1. **Chappell2008 (HMEF, NCT00233025)**
* Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomised clinical trial of duloxetine for the treatment of fibromyalgia. International journal of general medicine 2008;1:91-102.
* <https://clinicaltrials.gov/ct2/show/NCT00233025>
1. **Chappell2009 (HMEP, NCT00408421)**
* Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, Bennett RM, Collins H. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomised, placebo-controlled trial. Pain 2009;146(3):253-60.
* <https://clinicaltrials.gov/ct2/show/NCT00408421>
1. **Chappell2011 (HMFG, NCT00433290)**
	* Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, Brown JP. A double-blind, randomised, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain practice : the official journal of World Institute of Pain 2011;11(1):33-41.
	* <https://clinicaltrials.gov/ct2/show/NCT00433290>
2. **Davidson2008 (HMDV, NCT00122863)**
	* Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 2008;18(9):673-81.
	* <https://clinicaltrials.gov/ct2/show/NCT00122863>
3. **Detke2002a (HMBH Study Group A)**
* Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for majordepressive disorder: a randomised double-blind placebo-controlled trial. JClin Psychiatry. 2002 Apr;63(4):308-15.z
1. **Detke2002b (HMBH Study Group B)**
* Detke MJ, Lu Y, Goldstein D, McNamara R, Demitrack M. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90.
1. **Detke2004 (HMAY Study Group A)**
* Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004; 14: 457–70.
1. **Dmochowski2003 (SBAV)**
* Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. The Journal of urology 2003;170(4 Pt 1):1259-63.
1. **Frakes2011 (HMGL, NCT01018680)**
* Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomised, double-blind, placebo-controlled trial. Current medical research and opinion 2011;27(12):2361-72.
* <https://clinicaltrials.gov/ct2/show/NCT01018680>
1. **Gao2010 (HMEQ, NCT00408993)**
* Gao Y, Ning G, Jia WP, Zhou ZG, Xu ZR, Liu ZM, Liu C, Ma JH, Li Q, Cheng LL, Wen CY, Zhang SY, Zhang Q, Desaiah D, Skljarevski V. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chinese medical journal 2010;123(22):3184-92.
* <https://clinicaltrials.gov/ct2/show/NCT00408993>
1. **Gao2015 (HMGV, NCT01179672)**
* Gao Y, Guo X, Han P, Li Q, Yang G, Qu S, Yue L, Wang CN, Skljarevski V, Dueñas H, Raskin J, Gu L. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo. International journal of clinical practice 2015;69(9):957-66.
* <https://clinicaltrials.gov/ct2/show/NCT01179672>
1. **Gaynor2011a (HMGR, NCT01000805)**
* Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB. A randomised placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Current medical research and opinion 2011;27(10):1849-58.
* <https://clinicaltrials.gov/ct2/show/NCT01000805>
1. **Gaynor2011b (HMGU, NCT01070329)**
* Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Hann D, Marangell LB. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Current medical research and opinion 2011;27(10):1859-67**.**
* <https://clinicaltrials.gov/ct2/show/NCT01070329>
1. **Ghoniem2005 (SBAF, NCT00190606)**
* Ghoniem GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD, Yalcin I, Bump RC. A randomised controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. The Journal of urology 2005;173(5):1647-53**.**
* <https://clinicaltrials.gov/ct2/show/NCT00190606>
1. **Goldstein2004 (HMAT – Study Group B)**
* Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004; 24: 389–99.
1. **Goldstein2005 (HMAW)**
* Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116(1-2):109-18.
1. **Hartford2007 (HMDU, NCT00122850)**
* Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. International clinical psychopharmacology 2007;22(3):167-74.
* <https://clinicaltrials.gov/ct2/show/NCT00122850>
1. **Hellerstein2012 (#4967/6363R, NCT00360724)**
* Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y. A randomised controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. The Journal of clinical psychiatry 2012;73(7):984-91.
* <https://clinicaltrials.gov/ct2/show/NCT00360724>
1. **Kinchen2005 (SBBA)**
* Kinchen KS, Obenchain R, Swindle R. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. International urogynecology journal and pelvic floor dysfunction 2005;16(5):337-44.
1. **Konno2016 (HMGY, NCT01855919)**
* Konno S, Oda N, Ochiai T, Alev L. Randomised, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain. Spine 2016;41(22):1709-17.
* <https://clinicaltrials.gov/ct2/show/NCT01855919>
1. **Koponen2007 (HMBR, NCT00122824)**
* Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Primary care companion to the Journal of clinical psychiatry 2007;9(2):100-7.
* <https://clinicaltrials.gov/ct2/show/NCT00122824>
1. **Lin2008 (SBBT, NCT00475358)**
* Lin AT, Sun MJ, Tai HL, Chuang YC, Huang ST, Wang N, Zhao YD, Beyrer J, Wulster-Radcliffe M, Levine L, Chang C, Viktrup L. Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomised, placebo-controlled trial. BMC urology 2008;8:2**.**
* <https://clinicaltrials.gov/ct2/show/NCT00475358>
1. **Mah2006 (SBBU, NCT00475397)**
* Mah SY , Lee KS , Choo MS , Seo JT , Lee JZ , Park WH , Kim JC, Lee SY , Zhao YD , Beyrer J , Meghan Wulster-Radcliffe9 , Louise Levine9 , Lars Viktrup9Duloxetine versus Placebo for the Treatment of Korean Women with Stress Predominant Urinary Incontinence. Korean J Urol 2006;47:527-535
* <https://clinicaltrials.gov/ct2/show/NCT00475397>
1. **Mahableshwarkar2013 (NCT00672620)**
* Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomised, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29(3):217-26.
* <https://clinicaltrials.gov/ct2/show/NCT00672620>
1. **Mahableshwarkar2015a (NCT001153009)**
* Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomised, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015;232(12):2061-70.
* <https://clinicaltrials.gov/ct2/show/NCT001153009>
1. **Mahableshwarkar2015b (NCT01564862)**
* Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomised, Placebo Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015;40(8):2025-37.
* <https://clinicaltrials.gov/ct2/show/NCT01564862>
1. **Millard2004 (SBAX)**
* Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomised clinical trial. BJU international 2004;93(3):311-8.
1. **Mundt2007 (HQAC)**
* Mundt JC, Debrota DJ, Greist JH. Anchoring perceptions of clinical change on accurate recollection of the past: memory enhanced retrospective evaluation of treatment (MERET). Psychiatry (Edgmont (Pa. : Township)) 2007;4(3):39-45.
1. **Murakami2015 (HMGZ, NCT01552057)**
* Murakami M, Osada K, Mizuno H, Ochiai T, Alev L, Nishioka K. A randomised, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis research & therapy 2015;17:224.
* <https://clinicaltrials.gov/ct2/show/NCT01552057>
1. **Nicolini2009 (HMDW, NCT00122837)**
* Nicolini H, Bakish D, Duenas H, Spann M, Erickson J, Hallberg C, Ball S, Sagman D, Russell JM. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychological medicine 2009;39(2):267-76.
* <https://clinicaltrials.gov/ct2/show/NCT00122837>
1. **Nierenberg2007 (F1J-MC-HMCR, NCT00073411, Pigott 2007)**
* Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007; 23: 401–16.
* <https://clinicaltrials.gov/ct2/show/NCT00073411>
1. **Perahia2006 (HMAY - Study Group B)**
* Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006; 21: 367–78.
1. **Perahia2009 (HMDI, NCT00105989)**
* Perahia DG, Maina G, Thase ME, Spann ME, Wang F, Walker DJ, Detke MJ. Duloxetine in the prevention of depressive recurrences: a randomised, double-blind, placebo-controlled trial. The Journal of clinical psychiatry 2009;70(5):706-16.
* <https://clinicaltrials.gov/ct2/show/NCT00105989>
1. **Raskin2005 (HMAV – Study Group B, NCT00058968)**
* Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF. A double-blind, randomised multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain medicine (Malden, Mass.) 2005;6(5):346-56.
* <https://clinicaltrials.gov/ct2/show/NCT00058968>
1. **Reckziegel2017 (13124, NCT02208778)**
* Reckziegel D, Bailey H, Cottam WJ, Tench CR, Mahajan RP, Walsh DA, Knaggs RD, Auer DP. Imaging pain relief in osteoarthritis (IPRO): protocol of a double-blind randomised controlled mechanistic study assessing pain relief and prediction of duloxetine treatment outcome. BMJ open 2017;7(6):e014013**.**
* <https://clinicaltrials.gov/ct2/show/NCT02208778>
1. **Russel2008 (HMCJ, NCT00190866)**
* Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomised, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136(3):432-44.
* <https://clinicaltrials.gov/ct2/show/NCT00190866>
1. **Rynn2008 (HMDT, NCT00475969)**
* Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and anxiety 2008;25(3):182-9.
* <https://clinicaltrials.gov/ct2/show/NCT00475969>
1. **Skljarevski2009 (HMEO, NCT00408876)**
* Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, Detke M, Backonja M. A double-blind, randomised trial of duloxetine versus placebo in the management of chronic low back pain. European journal of neurology 2009;16(9):1041-8.
* <https://clinicaltrials.gov/ct2/show/NCT00408876>
1. **Skljarevski2010a (HMEN, NCT00424593)**
* Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010;35(13):E578-85.
* <https://clinicaltrials.gov/ct2/show/NCT00424593>
1. **Skljarevski2010b (HMGC, NCT00767806)**
* Skljarevski V, Zhang S, Desaiah D, Alaka KJ, Palacios S, Miazgowski T, Patrick K. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomised, double-blind trial. The journalof pain: official journal of the American Pain Society 2010;11(12):1282-90.
* <https://clinicaltrials.gov/ct2/show/NCT00767806>
1. **Sofat2017 (11.0126, NCT02612233)**
* Sofat N, Harrison A, Russell MD, Ayis S, Kiely PD, Baker EH, Barrick TR, Howe FA. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis. Journal of pain research 2017;10:2437-49.
* <https://clinicaltrials.gov/ct2/show/NCT02612233>
1. **Study F1J-JE-323G**
2. **Study F1J-MC-HMAG**
3. **Study F1J-MC-HMAH**
4. **Study F1J-MC-HMAI**
5. **Study F1J-MC-HMAT – Group A**
6. **Study F1J-MC-HMGP**
7. **Study F1J-MC-SAAA**
8. **Study F1J-MC-SAAL**
9. **Study F1J-MC-SAAH**
10. **Study F1J-MC-SBAB**
11. **Study F1J-MC-SBBL**
12. **Study 1208.10 (NCT02232555)**
* <https://clinicaltrials.gov/ct2/show/NCT02232555>
1. **Study 33CL231 (NCT00603265)**
* <https://clinicaltrials.gov/ct2/show/NCT00603265>
1. **Study IRB00003943 (NCT00619983)**
* <https://clinicaltrials.gov/ct2/show/NCT00619983>
1. **Study M06-850 (NCT00507936)**
* <https://clinicaltrials.gov/ct2/show/NCT00507936>
1. **Study Dulo2006 (EudraCT: 2006-005506-32)**
* <https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005506-32/DK>
1. **Tétreault2016 (STU00039556, NCT01558700)**
* Tétreault P, Mansour A, Vachon-Presseau E, Schnitzer TJ, Apkarian AV, Baliki MN. Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials. PLoS biology 2016;14(10):e1002570.
* <https://clinicaltrials.gov/ct2/show/NCT01558700>
1. **Tourian2009 (3151A1-335, NCT00384033)**
* Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomised, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clinical therapeutics 2009;31 Pt 1:1405-23.
* <https://clinicaltrials.gov/ct2/show/NCT00384033>
1. **Uchio2018 (HMGX, NCT02248480)**
* Uchio Y, Enomoto H, Alev L, Kato Y, Ishihara H, Tsuji T, Ochiai T, Konno S. A randomised, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis. Journal of pain research 2018;11:809-21**.**
* <https://clinicaltrials.gov/ct2/show/NCT02248480>
1. **Van Kerrebroeck2004 (SBAT)**
* van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndaele JJ, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG : an international journal of obstetrics and gynaecology 2004;111(3):249-57.
1. **Wang2017 (HMGS, NCT01931475)**
* Wang G, Bi L, Li X, Li Z, Zhao D, Chen J, He D, Wang CN, Dueñas H, Skljarevski V, Yue L. Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomised, double-blind, placebo-controlled study. Osteoarthritis and cartilage 2017;25(6):832-8.
* <https://clinicaltrials.gov/ct2/show/NCT01931475>
1. **Wernicke2006 (HMAV – Study Group A)**
* Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J. A randomised controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67(8):1411-20.
1. **Yasuda2011 (HMFX, NCT00552175)**
* Yasuda H, Hotta N, Nakao K, Kasuga M, Kashiwagi A, Kawamori R. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomised controlled trial in Japan. Journal of diabetes investigation 2011;2(2):132-9.
* <https://clinicaltrials.gov/ct2/show/NCT00552175>
1. **Zinner1998 (SAAB)**
* Zinner, N., Sarshik, S., Faries, D. et al. Efficacy and safety of duloxetine in stress urinary incontinence patients: a double-blind, placebo-controlled multiple dose study. Neurourol Urodyn. 1998; 17: 173–174.